Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company focusing on breast cancer and other breast conditions. $ATOS

[Atossa Therapeutics @atossainc]

Scientific discovery often leads to new questions.

Atossa Therapeutics continues investigating where the biology of investigational (Z)-endoxifen may have relevance, with research spanning multiple breast cancer settings and select rare diseases.

Learn more about our work: https://t.co/2Jv0kZ3POQ $ATOS

[Atossa Therapeutics @atossainc]

Duchenne muscular dystrophy is best known as a muscle disease, but its biology extends well beyond muscle loss.

Atossa Therapeutics is exploring investigational (Z)-endoxifen based on mechanisms that may support future research in DMD.

Learn more: https://t.co/GFaeYwiHK1 $ATOS

[Atossa Therapeutics @atossainc]

One reason Atossa Therapeutics continues studying ESR1 mutations is their association with endocrine resistance in ER-positive breast cancer.

Understanding how investigational (Z)-endoxifen interacts across clinically relevant ESR1 mutations remains an important area of our research.

Learn more: https://t.co/hkhYwPKVOR $ATOS

[Atossa Therapeutics @atossainc]

Combination strategies remain an important area of breast cancer research.

In preclinical studies published in npj Breast Cancer, select novel (Z)-endoxifen-related compounds demonstrated additive to synergistic activity with the CDK4/6 inhibitor abemaciclib in certain experimental settings and models.

ICYMI, read the release: https://t.co/cZ8r0yDP8a $ATOS

[Atossa Therapeutics @atossainc]

Many breast cancer therapies begin their clinical journey in metastatic disease.

Atossa Therapeutics has also focused on earlier treatment settings, studying investigational (Z)-endoxifen in newly diagnosed patients to better understand its biologic activity before surgery.

Learn more: https://t.co/fWQgvMurZO $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics reported second quarter 2026 financial results and provided a corporate update, highlighting continued progress for (Z)-endoxifen across rare diseases and breast cancer.

During the quarter, Atossa presented new data at AACR and ASCO and published research supporting the continued development of (Z)-endoxifen.

Read more: https://t.co/2qnwUXa6us $ATOS

[Atossa Therapeutics @atossainc]

McCune-Albright syndrome is a rare genetic disorder that can cause early puberty and other endocrine abnormalities.

Atossa Therapeutics is investigating investigational (Z)-endoxifen as part of our commitment to addressing areas of significant unmet medical need.

Learn more: https://t.co/hkhYwPKVOR $ATOS

[Atossa Therapeutics @atossainc]

Recent milestones, including the KARISMA publication and presentations at ASCO 2026, continue to build the clinical evidence supporting investigational (Z)-endoxifen across multiple breast cancer settings.

CFO Mark Daniel discusses those developments and Atossa Therapeutics' broader pipeline strategy in Meet the Company from @‌TheFlyNews.

Read more: https://t.co/mSaNmewsGM $ATOS

[Atossa Therapeutics @atossainc]

Throughout our clinical programs, Atossa Therapeutics incorporates biomarkers to better understand how investigational (Z)-endoxifen interacts with disease biology.

Every dataset helps answer a different scientific question.

Learn more: https://t.co/JNzljcHUCQ $ATOS

[Atossa Therapeutics @atossainc]

Expanding into rare diseases marks an important step in Atossa Therapeutics' long-term strategy.

Senior Vice President of Research & Development Janet Rea joined @eHealthRadio to discuss the company's rare disease pipeline, investigational (Z)-endoxifen and the evolving regulatory landscape.

🎙️Listen: https://t.co/iywbNlhzuU $ATOS

[Atossa Therapeutics @atossainc]

Breast cancer treatment continues to evolve as researchers work to better match therapies to individual patients.

In a new interview, Atossa Therapeutics Senior Vice President of Research & Development Janet Rea discusses investigational (Z)-endoxifen, biomarker-driven treatment decisions and evolving approaches to ER-positive breast cancer.

Read via @DrugDiscoverDev: https://t.co/3nzm2NGCsl $ATOS

[Atossa Therapeutics @atossainc]

Current approaches for MAS-related peripheral precocious puberty primarily focus on reducing estrogen production.

Recently presented research from Atossa Therapeutics explores investigational (Z)-endoxifen as a mechanism-driven strategy designed to address additional downstream signaling pathways.

Learn more: https://t.co/S87bjBxKJT $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to investigational (Z)-endoxifen.

Five novel compounds demonstrated anti-cancer activity in ER-positive breast cancer models, including clinically relevant ESR1 mutations.

Read more: https://t.co/cZ8r0yDP8a $ATOS @Nature_NPJ

[Atossa Therapeutics @atossainc]

Two published reviews. Two unrelated diseases. One molecule.

Atossa CEO @quay_dr speaks with @medresearchnews about estrogen receptor biology in breast cancer, where it is well studied, and in skeletal muscle, where it led the team toward Duchenne muscular dystrophy.

Read the interview: https://t.co/3oUwRjU2f4 $ATOS

[Atossa Therapeutics @atossainc]

Our research in rare diseases builds on years of studying the biology of investigational (Z)-endoxifen.

Today, Atossa Therapeutics is exploring that science in McCune-Albright syndrome and Duchenne muscular dystrophy, where significant unmet medical needs remain.

Learn more: https://t.co/KEhKrwVnc7 $ATOS

[Atossa Therapeutics @atossainc]

That's a wrap on #AACRRareCancers26.

Thank you to everyone who connected with Senior Clinical Project Manager and Scientist Sandra S. Hammer, PhD, during the conference. We appreciated the thoughtful discussions around omics, rare cancers and emerging organoid models, and look forward to continuing those conversations. $ATOS

[Atossa Therapeutics @atossainc]

For decades, tamoxifen has been an important treatment option for hormone receptor-positive breast cancer. Its therapeutic activity, however, depends on the body's ability to convert it into endoxifen.

Atossa Therapeutics is studying the direct administration of investigational (Z)-endoxifen across multiple breast cancer settings, with research also expanding into select rare diseases.

Learn more about our science: https://t.co/T6vUiDAKa2 $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics presented preclinical data at #AACRRareCancers26 supporting a mechanism-driven approach to investigational (Z)-endoxifen in McCune-Albright syndrome.

The poster highlights dual modulation of estrogen receptor and PKC-β/AKT signaling as a potential therapeutic strategy for MAS-related peripheral precocious puberty.

Read more: https://t.co/S87bjBxKJT $ATOS

[Atossa Therapeutics @atossainc]

We're in Vancouver for day one of #AACRrarecancers26.

Atossa Therapeutics looks forward to connecting with researchers, clinicians and industry colleagues as discussions begin around advancing research for patients with rare cancers. $ATOS

[Atossa Therapeutics @atossainc]

We're looking forward to joining the rare cancer research community in Vancouver later this week for #AACRrarecancers26.

If you'll be attending and would like to connect with Sandra S. Hammer, PhD, from the Atossa Therapeutics team, send us a message. We look forward to the conversations ahead. $ATOS